R53 R41.3 F52.8 F52.0 M62.5
Conditions
Interventions
Group 1: 12 PFS subjects
At the time of patient presentation:
Medical history and physical examination are performed, including the collection of demographic data such as age, weight, and height.
Add
Sponsors
Institut für Humangenetik
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients under 50 years of age who have reported severe levels of persistent sexual, physical and neurological symptoms following use and discontinuation of finasteride and who are in contact with the PFS Network charity. The control group consists of fertile men under 50 years of age who have not taken finasteride and do not suffer from any sexual impairments. Age-matched male controls.
Exclusion criteria
Exclusion criteria: Under 18 years old, over 50 years old. No ability to travel.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigation of Finasteride-Induced Epigenetic Alterations and their Impact on Gene Expression These alterations can only be detected through laboratory-based analytical methods. Induced epigenetic changes—such as altered methylation patterns in androgen receptor (AR) regulatory regions or modifications in the chromatin landscape of androgen-responsive genes—are identified in the laboratory. These changes may underlie a pathologically altered sensitivity to androgens, potentially resulting in cytotoxicity and widespread dysregulation of gene expression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of PFS symptom severity via Likert responses and multiple validated measures by (IIEF, PHQ-9, SAPS, IPSS and AMS) and their correlation with the epigenetic changes | — |
Countries
Germany
Contacts
Public ContactFrank Sommer
Männergesundheit
Outcome results
None listed